Similarly, ARRB1-mediated inhibition of FOXO3a was reported to contribute to the growth of prostate cancer cells both in vitro and in vivo, an effect that was likely exerted via the promotion of cell proliferation and EMT (Kong et al., 2018). Here, FOXO3 is linked to prostate carcinoma.